



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



# COVID-19 Vaccination and Subclinical Axillary Lymphadenopathy on Mammogram: Correspondence

## From:

Rujittika Mungmunpantipantip, Viroj Wiwanitkit  
From the Consultant Unit, Private Academic Consultant, Bangkok Thailand (R.M.); Dr DY Patil University, Pune, India (V.W.).

**D**ear Editor, we read with interest the paper “COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram” by Raj et al. (1) where the authors concluded that women who have received either mRNA COVID-19 vaccines may benefit from scheduling their screening mammogram at least 8 weeks after the vaccination. We concur that lymphadenopathy after COVID-19 vaccination might cause a problem in interpreting the mammogram and that having the mammogram before vaccination is useful.

However, during the present pandemic, mass vaccination is needed, and it is often difficult to schedule a timely appointment for a mammogram. In cases in which it is not possible to have a prevaccination mammogram, a mammogram after vaccination is useful. Waiting for 10 weeks, similar to that recommended for nuclear imaging studies (2), might be appropriate. If the case is urgent, aiming at diagnostic not screening, the mammogram should be done without delay.

# Letter to the Editor

## AUTHORS CONTRIBUTIONS

### RM 50 % -

- 1a Substantial contributions to study conception and design.
- 1b. Substantial contributions to acquisition of data.
- 1c. Substantial contributions to analysis and interpretation of data.
2. Drafting the article or revising it critically for important intellectual content.
3. Final approval of the version of the article to be published.

### VW 50% -

- 1a Substantial contributions to study conception and design.
- 1b. Substantial contributions to acquisition of data.
- 1c. Substantial contributions to analysis and interpretation of data.
2. Drafting the article or revising it critically for important intellectual content.
3. Final approval of the version of the article to be published.

## REFERENCES

1. Raj S, Ogola G, Han J. COVID-19 vaccine-associated subclinical axillary lymphadenopathy on screening mammogram. *Acad Radiol* 2022; 29(4):501–507.
2. El-Sayed MS, Wechie GN, Low CS, et al. The incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on (18)F-FD. *Clin Med (Lond)* 2021; 21(6):e633–e638.

<https://doi.org/10.1016/j.acra.2021.12.024>